CCIA
IOVA icon

Campbell & Co Investment Adviser’s Iovance Biotherapeutics IOVA Stock Holding History

Campbell & Co Investment Adviser’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-112,277
Closed -$900K – 1214
2024
Q2 		$900K Buy
+112,277
New +$1.2M 0.08% 405
2021
Q4 		– Sell
-10,200
Closed -$252K – 708
2021
Q3 		$252K Buy
+10,200
New +$240K 0.08% 436

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Campbell & Co Investment Adviser's IOVA Position: Q3 2024 in Review

Campbell & Co Investment Adviser sold out of Iovance Biotherapeutics (IOVA) in Q3 2024, closing a stake of 112,277 shares — an estimated $900K sold.

Campbell & Co Investment Adviser first reported a position in IOVA in Q3 2021 and held it in 2 quarters. The position peaked at $900K in Q2 2024. 286 funds tracked by Wall St. Rank hold IOVA as of Q3 2024.

  • Campbell & Co Investment Adviser reported no remaining Iovance Biotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 112,277 Iovance Biotherapeutics shares in Q3 2024, an estimated $900K.
  • Campbell & Co Investment Adviser first reported a position in Iovance Biotherapeutics in Q3 2021 and held it in 2 quarters.
  • Campbell & Co Investment Adviser's Iovance Biotherapeutics position peaked at $900K in Q2 2024.
  • 286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2024.

Based on Campbell & Co Investment Adviser's 13F filing for Q3 2024, filed 12 Nov 2024.